Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Scientists at Stanford Medicine have engineered "tissue-resident" natural killer (NK) cells that can penetrate solid tumors — a major hurdle in cancer immunotherapy. In mice, these supercharged cells slowed melanoma and head and neck cancers, with even stronger results when paired with the antibody drug cetuximab. A Phase I clinical trial could launch by year's end.
Cell therapies have already transformed treatment for blood cancers, but solid tumors have stubbornly resisted — partly because immune cells struggle to get inside them. Now, researchers at Stanford Medicine think they've found a workaround. By briefly exposing natural killer (NK) cells to epithelial tumor cells that deliver a precise dose of a signaling protein called TGF-β, the team converted circulating NK cells into a specialized "tissue-resident" form that can infiltrate solid tumors and keep killing once inside.
In mouse models, these engineered cells slowed the growth of melanoma and head and neck squamous cell carcinoma. The effect was dramatically amplified when combined with cetuximab, a monoclonal antibody already approved for colorectal and head and neck cancers. Crucially, NK cells don't trigger immune rejection when transferred between people — meaning doses could be manufactured in bulk, frozen, and shipped like an off-the-shelf drug, potentially reaching far more patients than today's personalized cell therapies.
Key Takeaways:
Why it matters: Solid tumors account for the vast majority of cancer deaths, yet cell therapies have largely failed them. An accessible, off-the-shelf NK cell therapy that can breach tumor defenses could be a game-changer for patients with limited options.
